A Review on Current Nanomaterials and Their Drug Conjugate for Targeted Breast Cancer Treatment

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2017 Apr 11

PMID 28392694

Citations 29

Authors

Joanna Jinling Lee

Latifah Saiful Yazan

Che Azurahanim Che Abdullah

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common malignancy worldwide, especially among women, with substantial after-treatment effects. The survival rates of breast cancer have decreased over the years even with the existence of various therapeutic strategies, specifically, chemotherapy. Clinical drugs administered for breast cancer appear to be non-targeting to specific cancer sites leading to severe side effects and potentially harming healthy cells instead of just killing cancer cells. This leads to the need for designing a targeted drug delivery system. Nanomaterials, both organic and inorganic, are potential drug nanocarriers with the ability of targeting, imaging and tracking. Various types of nanomaterials have been actively researched together with their drug conjugate. In this review, we focus on selected nanomaterials, namely solid-lipid, liposomal, polymeric, magnetic nanoparticles, quantum dots, and carbon nanotubes and their drug conjugates, for breast cancer studies. Their advantages, disadvantages and previously conducted studies were highlighted.

Citing Articles

Anti-Cancer Potency of Copper-Doped Carbon Quantum Dots Against Breast Cancer Progression.

Wang M, Lan S, Zhang W, Jin Q, Du H, Sun X Int J Nanomedicine. 2024; 19:1985-2004.

PMID: 38435754 PMC: 10908338. DOI: 10.2147/IJN.S449887.

Preparation, Characterization, and Evaluation of Physcion Nanoparticles for Enhanced Oral Bioavailability: An Attempt to Improve Its Antioxidant and Anticancer Potential.

Khuda F, Zahir I, Khalil A, Ali S, Ullah N, Albariqi A ACS Omega. 2023; 8(37):33955-33965.

PMID: 37744808 PMC: 10515591. DOI: 10.1021/acsomega.3c04821.

Self-assembly of Hyaluronic Acid-Cu-Quercetin flavonoid nanoparticles: synergistic chemotherapy to target tumors.

Yue H, Zhao X, Yong Q, Shi M, Jiang X, Zhang Y PeerJ. 2023; 11:e15942.

PMID: 37663303 PMC: 10470444. DOI: 10.7717/peerj.15942.

Implantable Devices for the Treatment of Breast Cancer.

Pial M, Tomitaka A, Pala N, Roy U J Nanotheranostics. 2023; 3(1):19-38.

PMID: 37600442 PMC: 10438892. DOI: 10.3390/jnt3010003.

Nanodrugs systems for therapy and diagnosis of esophageal cancer.

Zhang L, Li X, Yue G, Guo L, Hu Y, Cui Q Front Bioeng Biotechnol. 2023; 11:1233476.

PMID: 37520291 PMC: 10373894. DOI: 10.3389/fbioe.2023.1233476.

References

Couvreur P . Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2012; 65(1):21-3. DOI: 10.1016/j.addr.2012.04.010. View

Kircheis R, Schuller S, Brunner S, Ogris M, Heider K, Zauner W . Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J Gene Med. 2000; 1(2):111-20. DOI: 10.1002/(SICI)1521-2254(199903/04)1:2<111::AID-JGM22>3.0.CO;2-Y. View

Huang H, Yuan Q, Shah J, Misra R . A new family of folate-decorated and carbon nanotube-mediated drug delivery system: synthesis and drug delivery response. Adv Drug Deliv Rev. 2011; 63(14-15):1332-9. DOI: 10.1016/j.addr.2011.04.001. View

Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, Syrjanen S . Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res. 1994; 11(8):1127-31. DOI: 10.1023/a:1018932714745. View

Frullano L, Meade T . Multimodal MRI contrast agents. J Biol Inorg Chem. 2007; 12(7):939-49. DOI: 10.1007/s00775-007-0265-3. View

Chidambaram M, Manavalan R, Kathiresan K . Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci. 2011; 14(1):67-77. DOI: 10.18433/j30c7d. View

Li M, Tang Z, Zhang Y, Lv S, Yu H, Zhang D . LHRH-peptide conjugated dextran nanoparticles for targeted delivery of cisplatin to breast cancer. J Mater Chem B. 2020; 2(22):3490-3499. DOI: 10.1039/c4tb00077c. View

Webster D, Sundaram P, Byrne M . Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm. 2013; 84(1):1-20. DOI: 10.1016/j.ejpb.2012.12.009. View

Lehner R, Wang X, Marsch S, Hunziker P . Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application. Nanomedicine. 2013; 9(6):742-57. DOI: 10.1016/j.nano.2013.01.012. View

10.

Mudshinge S, Deore A, Patil S, Bhalgat C . Nanoparticles: Emerging carriers for drug delivery. Saudi Pharm J. 2013; 19(3):129-41. PMC: 3744999. DOI: 10.1016/j.jsps.2011.04.001. View

11.

Karmakar A, Bratton S, Dervishi E, Ghosh A, Mahmood M, Xu Y . Ethylenediamine functionalized-single-walled nanotube (f-SWNT)-assisted in vitro delivery of the oncogene suppressor p53 gene to breast cancer MCF-7 cells. Int J Nanomedicine. 2011; 6:1045-55. PMC: 3124390. DOI: 10.2147/IJN.S17684. View

12.

Mukherjee S, Ray S, Thakur R . Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2010; 71(4):349-58. PMC: 2865805. DOI: 10.4103/0250-474X.57282. View

13.

Yezhelyev M, Gao X, Xing Y, Al-Hajj A, Nie S, ORegan R . Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2006; 7(8):657-67. DOI: 10.1016/S1470-2045(06)70793-8. View

14.

Ligresti G, Libra M, Militello L, Clementi S, Donia M, Imbesi R . Breast cancer: Molecular basis and therapeutic strategies (Review). Mol Med Rep. 2011; 1(4):451-8. View

15.

Alexis F, Pridgen E, Langer R, Farokhzad O . Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010; (197):55-86. DOI: 10.1007/978-3-642-00477-3_2. View

16.

Batra R, Davies J, Wheatley D . Extensive arterial and venous thrombo-embolism with chemotherapy for testicular cancer: a case report. Cases J. 2010; 2:9082. PMC: 2803879. DOI: 10.1186/1757-1626-2-9082. View

17.

Prato M, Kostarelos K, Bianco A . Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res. 2007; 41(1):60-8. DOI: 10.1021/ar700089b. View

18.

Day E, Bickford L, Slater J, Riggall N, Drezek R, West J . Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. Int J Nanomedicine. 2010; 5:445-54. PMC: 2950402. DOI: 10.2147/ijn.s10881. View

19.

Nie S . Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond). 2010; 5(4):523-8. PMC: 2913868. DOI: 10.2217/nnm.10.23. View

20.

Caracciolo G . Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. Nanomedicine. 2015; 11(3):543-57. DOI: 10.1016/j.nano.2014.11.003. View